Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 03 Apr 2025 Status changed from not yet recruiting to recruiting.
- 17 Mar 2025 Planned End Date changed from 1 Apr 2030 to 1 Jun 2030.
- 17 Mar 2025 Planned primary completion date changed from 1 Apr 2028 to 1 Jun 2028.